Literature DB >> 15047866

Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts.

Xu Shi-Wen1, Yunliang Chen, Christopher P Denton, Mark Eastwood, Elisabetta A Renzoni, George Bou-Gharios, Jeremy D Pearson, Michael Dashwood, Roland M du Bois, Carol M Black, Andrew Leask, David J Abraham.   

Abstract

The endothelins are a family of endothelium-derived peptides that possess a variety of functions, including vasoconstriction. Endothelin-1 (ET-1) is up-regulated during tissue repair and promotes myofibroblast contraction and migration, hence contributing to matrix remodeling during tissue repair. Here, we show that addition of ET-1 to normal lung fibroblasts induces expression of proteins that contribute to a contractile phenotype, including alpha-smooth muscle actin (alpha-SMA), ezrin, moesin, and paxillin. We confirm that ET-1 enhances the ability of lung fibroblasts to contract extracellular matrix, a function essential for tissue repair, through induction of de novo protein synthesis. Blockade of the Akt/phosphoinositide 3-kinase (PI3-kinase) pathway with LY294002 and wortmannin prevents the ability of ET-1 to induce alpha-SMA, ezrin, paxillin, and moesin and to promote matrix contraction. Dominant negative rac and Akt blocked the ability of ET-1 to promote formation of alpha-SMA stress fibers. Using specific ET-1 receptor inhibitors, we show that ET-1 induces collagen matrix contraction through the ETA, but not the ETB, receptor. Relative to normal pulmonary fibroblasts, fibroblasts cultured from scars of patients with the fibrotic disease systemic sclerosis (scleroderma) show enhanced ET-1 expression and binding. Systemic sclerosis lung fibroblasts show increased ability to contract a collagen matrix and elevated expression of the procontractile proteins alpha-SMA, ezrin, paxillin, and moesin, which are greatly reduced by antagonizing endogenous ET-1 signaling. Thus, blocking ET-1 or the PI3-kinase/Akt cascades might be beneficial in reducing scar formation in pulmonary fibrosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15047866      PMCID: PMC420095          DOI: 10.1091/mbc.e03-12-0902

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  84 in total

Review 1.  Invited review: cross-bridge regulation by thin filament-associated proteins.

Authors:  K G Morgan; S S Gangopadhyay
Journal:  J Appl Physiol (1985)       Date:  2001-08

Review 2.  Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway.

Authors:  A Brunet; S R Datta; M E Greenberg
Journal:  Curr Opin Neurobiol       Date:  2001-06       Impact factor: 6.627

3.  Cell locomotion forces versus cell contraction forces for collagen lattice contraction: an in vitro model of wound contraction.

Authors:  H P Ehrlich; J B Rajaratnam
Journal:  Tissue Cell       Date:  1990       Impact factor: 2.466

4.  Collagen synthesis and degradation by systemic sclerosis lung fibroblasts. Responses to transforming growth factor-beta.

Authors:  N K Harrison; A C Argent; R J McAnulty; C M Black; B Corrin; G J Laurent
Journal:  Chest       Date:  1991-03       Impact factor: 9.410

Review 5.  Endothelins.

Authors:  E E Anggård; R M Botting; J R Vane
Journal:  Blood Vessels       Date:  1990

6.  Thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via the proteolytically activated receptor-1 and a protein kinase C-dependent pathway.

Authors:  G S Bogatkevich; E Tourkina; R M Silver; A Ludwicka-Bradley
Journal:  J Biol Chem       Date:  2001-09-28       Impact factor: 5.157

7.  Smooth muscle differentiation in scleroderma fibroblastic cells.

Authors:  A P Sappino; I Masouyé; J H Saurat; G Gabbiani
Journal:  Am J Pathol       Date:  1990-09       Impact factor: 4.307

Review 8.  Paxillin: a focal adhesion-associated adaptor protein.

Authors:  M D Schaller
Journal:  Oncogene       Date:  2001-10-01       Impact factor: 9.867

Review 9.  Endothelins.

Authors:  G M Rubanyi; L H Botelho
Journal:  FASEB J       Date:  1991-09       Impact factor: 5.191

10.  Modulation of contraction by gelation/solation in a reconstituted motile model.

Authors:  L W Janson; J Kolega; D L Taylor
Journal:  J Cell Biol       Date:  1991-09       Impact factor: 10.539

View more
  120 in total

Review 1.  Molecular pathophysiology of priapism: emerging targets.

Authors:  Uzoma A Anele; Belinda F Morrison; Arthur L Burnett
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

2.  Urotensin-II in systemic sclerosis: a new peptide in pathogenesis.

Authors:  Yavuz Pehlivan; Ahmet Mesut Onat; Gazi Comez; Taner Babacan
Journal:  Clin Rheumatol       Date:  2011-01-28       Impact factor: 2.980

3.  Survivin expression induced by endothelin-1 promotes myofibroblast resistance to apoptosis.

Authors:  Jeffrey C Horowitz; Iyabode O Ajayi; Priya Kulasekaran; David S Rogers; Joshua B White; Sarah K Townsend; Eric S White; Richard S Nho; Peter D R Higgins; Steven K Huang; Thomas H Sisson
Journal:  Int J Biochem Cell Biol       Date:  2011-10-25       Impact factor: 5.085

Review 4.  The role of connective tissue growth factor (CTGF/CCN2) in skeletogenesis.

Authors:  John A Arnott; Alex G Lambi; Christina Mundy; Honey Hendesi; Robin A Pixley; Thomas A Owen; Fayez F Safadi; Steven N Popoff
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2011       Impact factor: 1.807

Review 5.  Medical therapies for pulmonary arterial hypertension.

Authors:  Tomas Pulido; Nayeli Zayas; Maitane Alonso de Mendieta; Karen Plascencia; Jennifer Escobar
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

Review 6.  Cardioprotective signaling by endothelin.

Authors:  Anita Schorlemmer; Michelle L Matter; Ralph V Shohet
Journal:  Trends Cardiovasc Med       Date:  2008-10       Impact factor: 6.677

Review 7.  Interstitial lung disease in systemic sclerosis.

Authors:  Predrag Ostojic; Marco Matucci Cerinic; Richard Silver; Kristin Highland; Nemanja Damjanov
Journal:  Lung       Date:  2007 Jul-Aug       Impact factor: 2.584

Review 8.  Recent advances in understanding the pathogenesis of scleroderma-interstitial lung disease.

Authors:  Tanjina Akter; Richard M Silver; Galina S Bogatkevich
Journal:  Curr Rheumatol Rep       Date:  2014-04       Impact factor: 4.592

9.  Whole animal knockout of smooth muscle alpha-actin does not alter excisional wound healing or the fibroblast-to-myofibroblast transition.

Authors:  James J Tomasek; Carol J Haaksma; Robert J Schwartz; Eric W Howard
Journal:  Wound Repair Regen       Date:  2012-12-18       Impact factor: 3.617

Review 10.  Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials.

Authors:  Karen Au; Dinesh Khanna; Philip J Clements; Daniel E Furst; Donald P Tashkin
Journal:  Curr Rheumatol Rep       Date:  2009-04       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.